IMRX ▲ +1.6% - Immuneering Corporation
$IMRX - Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer
12-NOV-2026 07:30 AM ET
Share this post
More filings for $IMRX
IMRX ▼ -1.9% - Immuneering CorporationNov 9, 2026IMRX ▼ -0.3% - Immuneering CorporationNov 4, 2026IMRX ▲ +0.5% - Immuneering CorporationOct 29, 2026IMRX ▼ -2.4% - Immuneering CorporationOct 26, 2026IMRX ▲ +4.2% - Immuneering CorporationOct 2, 2026IMRX ▲ +2.1% - Immuneering CorporationSep 28, 2026
View full $IMRX filing history →💬 Comments
Loading comments…
Leave a comment